Photo Release -- CytoSorbents Provides Update on ISICEM 2013 Critical Care Conference

Photo Release -- CytoSorbents Provides Update on ISICEM 2013 Critical Care
Conference

Significant Interest Generated from Distributors and Key Opinion Leaders

MONMOUTH JUNCTION, N.J., March 26, 2013 (GLOBE NEWSWIRE) -- CytoSorbents
Corporation (OTCBB:CTSO), a critical care focused company using blood
purification to treat life-threatening illnesses, provides an update on its
recent exhibition at the 33^rd International Symposium on Intensive Care and
Emergency Medicine (ISICEM)in Brussels, Belgium last week. This year,
approximately 6,000 participants from all over the world attended for an
up-to-date review of the most recent, clinically relevant, developments in
research, therapy, and management of the critically ill.

CytoSorbents Booth
 CytoSorbents Newly Re-designed Booth at
 ISICEM 2013 Critical Care Conference

A photo accompanying this release is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=17789

At its newly re-designed booth (see picture inset), CytoSorbents featured its
flagship product, CytoSorb®, the only specifically approved cytokine blood
filter in the European Union.The goal of CytoSorb® is to prevent or treat
organ failure - the cause of nearly half of all deaths in the ICU - by
controlling "cytokine storm" and reducing deadly inflammation.CytoSorb® has
now been used in many different critical care applications, and is generating
revenue through direct sales in primarily Germany and Austria, where
reimbursement exists. It is also approved for sale throughout all 27 European
Union countries, and can be sold, with proper registration, in many other
countries outside the E.U.

Dr. Phillip Chan, Chief Executive Officer of CytoSorbents, stated, "This
ISICEM symposium was one of our most productive conferences we have had to
date and we were pleased with the new and ongoing interest in CytoSorb®.Our
mindshare amongst clinicians has clearly increased since last year's
conference and our booth traffic was very steady, with potential new customers
and existing key opinion leaders who are collaborating with us on additional
clinical studies. During our time in Brussels, we advanced our discussions
with distributors from many major countries as well as potential strategic
corporate partners.This is consistent with our strategy to aggressively
expand commercialization of CytoSorb® in order to drive future significant
revenue growth through both direct and partner sales."

Dr. Chan continued, "At the meeting, our collaborator Dr. John Kellum from
University of Pittsburgh Medical Center, spoke to an audience of more than 300
people on 'Reversing sepsis-induced immune suppression' based on findings from
his recently published article in the scientific journal, Molecular Medicine,*
using our CytoSorb® technology.Dr. Kellum highlighted how a reduction of
"cytokine storm" using CytoSorb® in rat models of sepsis can allow the immune
system to target the true area of infection more efficiently, while reducing
unintentional injury by immune cells to otherwise healthy vital organs like
the lungs, liver and kidneys.We believe this is one of the key mechanisms of
action by which CytoSorb® may prevent or treat organ failure in humans."

"Additionally, Dr. Dirk Schädler, from the Kiel University presented his
poster, entitled, "A multicenter randomized controlled study of an
extracorporeal cytokine hemoadsorption device in septic patients."This
poster can be found on our investor website at:
http://www.cytosorbents.com/invest.htm.Interestingly, an entire session was
also devoted to the deadly risks of blood transfusion in critically-ill
patients, highlighting the value of our HemoDefend blood purification
technology that aims to reduce adverse events related to administering blood."

Dr. Chan concluded, "If one looks at the range of research topics covered at
ISICEM, one thing is very clear.CytoSorb® is targeting some of the most
important unmet medical needs in the ICU. The continued lack of effective
therapies for critically-ill patients is remarkable, particularly in the area
of controlling inflammation and treating organ failure, making the opportunity
for CytoSorb® that much more compelling.If it works as intended, CytoSorb®
has the real potential to revolutionize critical care therapy."

*Namas, RA, et al., "Hemoadsorption reprograms inflammation in experimental
gram-negative septic peritonitis:Insights from in vivo and in silico studies"
Molecular Medicine, 2012, vol. 18, p. 1366-1374.

About CytoSorbents

CytoSorbents Corporation is a critical care focused therapeutic device company
using blood purification to modulate the immune system and fight multi-organ
failure in life-threatening illnesses.Its purification technology is based on
biocompatible, highly porous polymer beads that can actively remove toxic
substances from blood and other bodily fluids by pore capture and
adsorption.CytoSorb®, the Company's flagship product, is approved in the
European Union as a safe and effective cytokine filter, designed to reduce the
"cytokine storm" that could otherwise cause massive inflammation, organ
failure and death in common critical illnesses such as sepsis, burn injury,
trauma, lung injury, and pancreatitis.These are conditions where the
mortality is extremely high, yet no effective treatments exist.Additional
information is available on the Company's website:
http://www.cytosorbents.com.

Forward-Looking Statements

This press release includes forward-looking statements intended to qualify for
the safe harbor from liability established by the Private Securities
Litigation Reform Act of 1995. Forward-looking statements in this press
release are not promises or guarantees and are subject to risks and
uncertainties that could cause our actual results to differ materially from
those anticipated. These statements are based on management's current
expectations and assumptions and are naturally subject to uncertainty and
changes in circumstances. We caution you not to place undue reliance upon any
such forward-looking statements. Actual results may differ materially from
those expressed or implied by the statements herein. CytoSorbents Corporation
and CytoSorbents, Inc believe that its primary risk factors include, but are
not limited to: obtaining government approvals including required FDA and
additional CE Mark approvals; ability to successfully develop commercial
operations; dependence on key personnel; acceptance of the Company's medical
devices in the marketplace; the outcome of pending and potential litigation;
compliance with governmental regulations; reliance on research and testing
facilities of various universities and institutions; the ability to obtain
adequate and timely financing in the future when needed; product liability
risks; limited manufacturing experience; limited marketing, sales and
distribution experience; market acceptance of the Company's products;
competition; unexpected changes in technologies and technological advances;
and other factors detailed in the Company's Form 10-K filed with the SEC on
March 30, 2012, which is available at http://www.sec.gov.

CONTACT: Company Contact:
         CytoSorbents Corporation
         Dr. Phillip Chan
         Chief Executive Officer
         (732) 329-8885 ext. *823
         pchan@cytosorbents.com
        
         Investor Contact:
         Alliance Advisors, LLC
         Alan Sheinwald
         (914) 669-0222
         asheinwald@allianceadvisors.net
        
         Valter Pinto
         (914) 669-0222 x201
         valter@allianceadvisors.net
 
Press spacebar to pause and continue. Press esc to stop.